Because we are technology agnostic, we have the freedom to think big and broad.
We work with experts in Duchenne muscular dystrophy (Duchenne) and across the industry to ensure our clinical trial design and execution is conducted with the utmost respect for patient safety and well-being.
We understand the decision to participate in any clinical research is not made lightly and are incredibly grateful to those patients and families who choose to do so. We are also thankful for the dedicated staff and clinicians at the hospitals and clinics that help conduct and support the research.
Learn more about Solid Biosciences’ current ongoing Phase I/II clinical trial, IGNITE-DMD. Search for study ID number: NCT03368742 at clinicaltrials.gov.